Introduction and Objectives to Advances in Targeted Therapy for Small Cell Lung Cancer
Ticiana Leal, MD, discusses how recently approved targeted therapies for small cell lung cancer (SCLC) significantly enhance survival outcomes and reshape treatment strategies for both limited and extensive stages of the disease.
Video content above is prompted by the following:
1. Describe the case and your initial impressions:.
2. What would be the predominant goals of therapy for a patient such as this?
3. In patients with extensive stage SCLC small cell lung cancer (ES-SCLC)that has developed progression, how do you balance the survival benefits afforded by subsequent lines of therapy with risks of treatment-related adverse events after progression of disease on platinum-based primary therapy?
Related Content
